Drugs / Bacillus coagulans
Bacillus coagulans
also known as
GanedenBC30 · B coagulans · Bacillus Coagulans GBI-30, 6068 · Bacillus coagulans GBI-30, 6086 · GBI-30 · PTA-6086
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT01184456 | Aug 2010 → Jul 2012 | HIV infectious disease | AIDS Healthcare Foundation | Completed | No outcome recorded |
| Phase 44 trials | ||||||
| Phase 4 | NCT07187492 | Sep 2025 → Oct 2026 expected | anxiety, depressive disorder, dyspepsia | Xijing Hospital of Digestive Diseases | Recruiting | No outcome recorded |
| Phase 4 | NCT05237115 | May → Dec 2020 | dyspepsia, gastritis, peptic ulcer disease | Xijing Hospital of Digestive Diseases | Completed | No outcome recorded |
| Phase 4 | NCT03857425 | Mar → Aug 2019 | Helicobacter pylori infectious disease, dyspepsia, gastritis | Xijing Hospital of Digestive Diseases | Completed | No outcome recorded |
| Phase 4 | NCT01337609 | Jun 2011 → Feb 2012 | irritable bowel syndrome, major depressive disorder | Massachusetts General Hospital | Terminated | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06593834 | Sep 2024 → Apr 2026 overdue | acute graft versus host disease | Yamin Fan | Not yet recruiting | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bacillus coagulans | “given for 14 days at a dose of Bacillus coagulans tablets 350mg 3 capsules BID, esomeprazole 40 mg BID, amoxicillin 500 mg 2 capsules BID, and clarithromycin 500 mg 1 tablet BID.” NCT05237115 ↗ |
| Known as | B coagulans | “This study aimed to assess the efficacy and safety of monotherapy with Clostridium butyricum (C butyricum) and Bacillus coagulans (B coagulans) for H pylori treatment.” PMID 33157939 ↗ Nov 2020 |
| Known as | Bacillus Coagulans GBI-30, 6068 | “A Double-Blind, Placebo-Controlled Study of the Probiotic Ganeden BC30 (Bacillus Coagulans GBI-30, 6068) in Irritable Bowel Syndrome Comorbid With Major Depressive Disorder (MDD)” NCT01337609 ↗ |
| Known as | Bacillus coagulans GBI-30, 6086 | “Arm 1 will take GanedenBC30 (Bacillus coagulans GBI-30, 6086, 1 capsule/day) for 60 days.” NCT01337609 ↗ |
| Known as | GanedenBC30 | “The purpose of this study is to determine the safety and effectiveness of a nutritional supplement, the probiotic bacteria GanedenBC30.” NCT01337609 ↗2“1 capsule per day containing 2 billion CFU of GanedenBC30, GBI-30, PTA-6086 for 90 days.” NCT01184456 ↗ |
| Known as | GBI-30 | “1 capsule per day containing 2 billion CFU of GanedenBC30, GBI-30, PTA-6086 for 90 days.” NCT01184456 ↗ |
| Known as | PTA-6086 | “1 capsule per day containing 2 billion CFU of GanedenBC30, GBI-30, PTA-6086 for 90 days.” NCT01184456 ↗ |
| Action | Inhibit | “CONCLUSION: C butyricum and B coagulans may effectively inhibit H pylori to some extent, with rare adverse events, and thus may reduce the burden of antibiotic resistance.” PMID 33157939 ↗ Nov 2020 |
| Modality | Other / unclassified | “DIETARY_SUPPLEMENT” NCT01184456 ↗ |